increasing use of PEOR data can be expected in future decision making processes.
The 72 respondents represented organizations with national (54%), regional (32%) and local coverage (14%).
Effectiveness

Results Conclusions
Requirements to Increase Use of HEOR in Decision Making
• PEOR is used often in decision making in the USA.
• However few organizations defined quality criteria at o a (5 %), eg o a (3 %) a d oca co e age ( %) Membership varied from 50,000 to 100 million with a median of 500,000. 
in Decision Making
Clear definition of HEOR data requirements 54%
More HEOR expertise in decision committee(s) 47%
Need for in-house data analysis 42%
• However, few organizations defined quality criteria for PEOR. Improved standards for quality control of such evidence are needed.
• There is a consistent expectation that the use of this data will increase.
• A concern is a lack of expertise to evaluate this information. Regular re-evaluation of decision 39%
Increased prospective data collection 36%
Collaboration across healthplans 25%
Strict request for dossiers in AMCP format 8%
No changes required 7%
• For the future, an increased use of HEOR data in decision making and contracting is expected.
Another survey will be targeted to the systems and decision makers in selected European and Asian countries to compare the utilization of PEOR in the different decision making environments
A major increase is expected in outcomes based contracting
Outcomes based evidence is already used in contracting (37%) today and 73% expect an increased use in future.
PEOR is broadly used today and increased use is expected in future
Major changes required 7% different decision making environments.
increased use is expected in future
While 70% of the respondents claimed that PEOR data are used regularly, only 5% indicated inclusion in the bylaws of their organizations. The majority of the respondents expected increasing use of PEOR in the future (77%).
Current Use of PEOR 29%
33%
Probably
To a limited degree Less off-label use
Other answers:
• Encourage manufacturers to identify target patients and train providers to do so
• Aligning incentives • Less waste • Improved safety and efficay
What standards are used for quality control ?
• One respondent referred to the 'Quality of Health Economic Studies' checklist (QHES).
A few used in house checklists Formulary Decisions are expected to be more patient centered in future
• A few used in-house checklists.
• Some team or committee decides on quality (outcomes team, external review team, P&T board) 
